Market closed · After hours · 6:35 PM ET
Last update: Sep 30, 2026, 6:20 PM ET
Liquidia Corporation
$30.26▼ 57.19% today
After Hours

Why Liquidia Corporation (LQDA) stock moved

Updated Sep 30, 2026

Liquidia Corporation (LQDA) shares tumbled 57.2% to $30.26 as of September 30, 2026, a sharp decline from the prior close of $70.69. BestStocks flagged the session as a major change for LQDA. Below, we break down what changed for LQDA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

LQDA fell 57.2% to $30.26

Liquidia shares collapsed 52.68% to $33.45 following a critical legal setback in its patent dispute with United Therapeutics over Yutrepia, per web reporting. Macro headwinds—rising Treasury yields, oil prices, and inflation data—compounded the selloff in biotech equities. Volume surged to 13.59x the time-adjusted average (15.1M shares), signaling panic liquidation. Confirmation of the court ruling details; earnings call on 2026-11-02 (date not yet confirmed) for management commentary on litigation impact and revised guidance.

This summary describes the catalyst and move as first detected on Sep 30, 2026, 12:52 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
ValuationMedium confidence
Rel. volume
13.4×
Extreme
Vs peers
—
No comparable peers
Market cap
$2.7B
NASDAQ Capital Market
Analyst target
$98
+224.2% vs price
Price chart
Aug 31 – Sep 30
VVVFNVVVF$30$52$74Aug 31Sep 8Sep 16Sep 23Sep 30
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Liquidia Corporation investors

For Liquidia Corporation investors, the recent signals add up to a bearish shift. On the constructive side: LQDA moved +5.83% from its $67.04 open to a $70.95 close on 2026-09-24; LQDA moved +3.08% from its $66.59 open to a $68.64 close on 2026-09-22. Weighing against that: Sharp 57.2% decline — elevated risk; High volume 13.4x on decline — distribution signal. Wall Street's consensus price target sits at $98.11, implying +224.2% upside from $30.26. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 33 days out, the next report is the most likely near-term test of the move.

LQDA price reaction

LQDA last traded at $30.26, down $40.43 (-57.19%) from the previous close of $70.69. The session traded on 13.4× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $30.26 and $73.67, and it currently sits about 0% of the way up that band.

Bullish and bearish analyst opinions on Liquidia Corporation (LQDA)

Latest catalysta bearish counterpoint
The latest catalyst — a materially negative development — a bearish counterpoint that challenges the prevailing bullish analyst view.

The consensus analyst price target on Liquidia Corporation (LQDA) is $98.11, 224.2% above the recent $30.26. Here is how the bullish and bearish cases on LQDA line up.

The bullish case

  • Wall Street's consensus price target of $98.11 implies +224.2% upside from $30.26.
  • The Street's most bullish target is $130.00 (+329.6%).
  • LQDA moved +5.83% from its $67.04 open to a $70.95 close on 2026-09-24.
  • LQDA moved +3.08% from its $66.59 open to a $68.64 close on 2026-09-22.
  • Liquidia Corporation (LQDA) moved +4.23% from $65.67 to $68.45 on 2026-09-16.

The bearish case

  • Sharp 57.2% decline — elevated risk.
  • High volume 13.4x on decline — distribution signal.
  • LQDA moved -4.70% from its $71.81 open to a $68.43 close on 2026-09-25.
  • Liquidia Corporation fell 6.46% to $73.70 following the filing of an earnings report and a material event (8-K) disclosed today, per SEC filings.
  • Liquidia Corporation shares fell 8.14% to $80.88 following today's earnings report filing and a same-day material event disclosure (8-K).
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Sep 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $98+224.2%
HC Wainwright & Co. maintained Buy · 2024-08-23
SEC filings watch
8-K2026-09-30
Material event — review for impact
high
8-K2026-09-03
Material event — review for impact
high
8-K2026-08-12
Material event — review for impact
high
10-Q2026-08-12
Quarterly financial results
medium
Peer context
LQDA-57.2%

Previous notable changes for LQDA

Filings2026-09-30
Liquidia Corporation (LQDA) filed a new 8-K on September 30, 2026.
News2026-09-30
YUTREPIA adoption generating profits and cash flow, establishing operating foundation for Liquidia's growth.
Valuation2026-09-28+7.7%via Yahoo Finance ↗
Liquidia Corporation moved +7.11% intraday from $68.43 to $73.30. Liquidia Corporation (LQDA) stock is surging today, up 7.22% to $73.37 in afternoon trading.The primary catalyst driving the upward momentum involves a major competitive shift in the pulmonary arterial hypertension (PAH) landscape: ### 🔎 Key Catalysts Driving the Rally - Competitor Downgrade Legal & Market Ripple Effects: Shares are catching a strong tailwind following a sharp Goldman Sachs downgrade on Liquidia's primary market rival, United Therapeutics (UTHR) . Goldman Sachs initiated coverage on UTHR with a Sell rating , explicitly citing shrinking core business lines and heavy market share erosion due to competition from Liquidia's primary drug, YUTREPIA. - YUTREPIA Market Dominance: Investors are rallying behind Liquidia as structural validation builds for its inhaled dry powder formulation, YUTREPIA. The drug recently captured roughly 30% of the inhaled prostacyclin market share , forcing United Therapeutics to report dropping sales for its competing Tyvaso lines. - Recent Fast Track Tailwinds: The stock is continuing to benefit from the broader momentum of the U.S. FDA recently granting Fast Track Designation to YUTREPIA for treating Raynaud's phenomenon. This regulatory c
Risk2026-09-25-3.6%
LQDA moved -4.70% from its $71.81 open to a $68.43 close on 2026-09-25.
Upcoming catalysts & outlook
Next earnings
2026-11-02 (est.)
in 33 days
10-Q Filing (est.)
2026-11-11
Medium impact
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about LQDA

Why did Liquidia Corporation (LQDA) stock move?

LQDA tumbled 57.2% to $30.26. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.

How much did LQDA stock fall?

LQDA lost 57.19% ($40.43) versus the prior close of $70.69, last trading at $30.26 on 13.4× average volume.

When is Liquidia Corporation's next earnings date?

LQDA's next earnings report is estimated for 2026-11-02 — about 33 days away.

What is the analyst price target for LQDA?

The consensus analyst price target for LQDA is $98.11, about 224.2% above the current $30.26. Over the past 90 days, analysts recorded 0 upgrades, 0 maintains, and 0 downgrades.

How BestStocks tracks LQDA

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LQDA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for LQDA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.